Advanced Filters
noise

Pain Clinical Trials

A listing of Pain medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,216 clinical trials
A A.C.M Van Den Bergh, MD PhD

Radiation-induced Toxicity in Prostate Cancer/ Standard-Follow-Up Program Prostate

The goal is to gain insight in the development and course of the toxicity after a curative treatment of prostate cancer

18 years of age Male Phase N/A

Epidemiologic and Genetic Study on Familial Prostate Cancer

The aims of the study are: to identify genetic and molecular factors (rare mutations, polymorphisms) involved in the natural history of prostate cancers and their response to treatment, to evaluate and deduce their medical applications for screening and therapeutic management of these tumors.

18 years of age All Phase N/A
R Ros Eeles

The i4i PRODICT™ Study: Evaluation of the i4i PRODICT™ Test in Different Ethnic Groups (The i4i PRODICT™ Study).

The i4i PRODICT™ study has been developed to investigate the uptake and acceptability of the i4i PRODICT™ test which combines both common and rare genetic changes (genetic variants) into one saliva-based DNA test to estimate a person's future risk of prostate cancer (PrCa) in people of varying ethnicities.

40 - 55 years of age Male Phase N/A
I Ismail Turkbey

Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)

The purpose of this study is to develop a new way to diagnose prostate cancer through the use of artificial intelligence. The goal is for this new method to reduce delays in diagnoses and to avoid invasive procedures such as biopsies.

18 - 89 years of age Male Phase N/A
A Andrea Salonia, MD

Observational Study of Patients Who Underwent Diagnostic Investigation (Prostate Biopsy) and/or Radical Prostatectomy Surgery.

This is a single-center, observational, prospective and retrospective study on quality of life and disease status of patients who underwent prostate biopsy and/or radical prostatectomy.

18 years of age Male Phase N/A
J Johann De-Bono

Microbiome Molecular Charaterisation

Preclinical models of prostate cancer have proved to be poorly predictive of the behaviour of the disease in patients. This protocol describes the acquisition of prostate cancer tissue or cells from patients with treatment naïve/hormone-sensitive and castration-resistant prostate cancer or patients undergoing diagnostic or follow up investigations. The knowledge gained …

18 years of age Male Phase N/A
E Elin Tragardh, Prof

AI-based Measurements of Tumour Burden in PSMA PET-CT

The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts …

20 - 120 years of age Male Phase N/A
H Hongqian Guo, Phd

Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer

Targeted and systematic biopsy stands as the prevalent diagnostic approach for prostate cancer. Despite its widespread use, this method is characterized by a high volume of needle biopsies. A refined approach, termed targeted and index-lesion-ipsilateral systematic biopsy, as one of targeted and regional systematic biopsy methods, aim to reduce the …

60 - 80 years of age Male Phase N/A
G Giulia Sorgentoni, PhD

ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

Study wants to explore real-world data in three distinct settings Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel _ARON-3S Patients receiving Lutetium-177 PSMA for mCRPC _ ARON-3Lu Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC _ ARON-3GEN

18 years of age All Phase N/A
S Shima Tayebi

Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)

Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite the approval of multiple systemic agents. Due to advances in screening …

22 years of age Male Phase N/A

Simplify language using AI